Unleash Immuno Oncolytics
Daniel Katzman is the CEO and founder of Unleash Immuno Oncolytics, a company that specializes in developing cancer treatments. Prior to founding Unleash Immuno Oncolytics, Katzman served as the CEO of Precision Virologics from August 2016 to May 2020. During their tenure at Precision Virologics, Katzman helped the company develop a new approach to the expanding threat of emerging infectious diseases.
Before joining Precision Virologics, Katzman served as the president of NeuroHealing Pharmaceuticals Inc. from July 2003 to November 2011. During their time at NeuroHealing Pharmaceuticals, Katzman was responsible for overseeing the company's research and development efforts. Under Katzman's leadership, NeuroHealing Pharmaceuticals developed several new treatments for neurological disorders.
Daniel Katzman has a MSc in Biochemistry from Universidad Nacional de La Plata and a Bachiller from Colegio Nacional de La Plata.
Louis J. Cantolupo - COO, Bradley Keller - VP, Preclinical Development report to Daniel Katzman.
Unleash Immuno Oncolytics
Unleash IO develops oncolytic immunotherapy products shown to be highly specific and efficacious in animal models and human tissue samples. Unleash IO’s leading product, UIO-512, is an oncolytic adenovirus that targets both malignant cells and tumor-associated stroma cells.